Prudential Financial’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
Other funds holding KYMR
BBA
ACA
BI
SL
Prudential Financial's KYMR Position: Q2 2026 in Review
Prudential Financial increased its Kymera Therapeutics (KYMR) stake by 116% in Q2 2026, buying an estimated $888K and bringing the position to 19,290 shares worth $2.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1362.
Prudential Financial first reported a position in KYMR in Q1 2021 and has held it in 14 quarters since. The position peaked at $5.78M in Q3 2024. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.
- Prudential Financial held 19,290 shares of Kymera Therapeutics worth $2.21M as of Q2 2026.
- Prudential Financial bought 10,340 Kymera Therapeutics shares in Q2 2026, an estimated $888K.
- Kymera Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #1362 holding.
- Prudential Financial first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 14 quarters since.
- Prudential Financial's Kymera Therapeutics position peaked at $5.78M in Q3 2024.
- 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.
Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.